| 3.985 0.185 (4.87%) | 07-26 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 6.25  |
1-year : | 7.67 |
| Resists | First : | 5.35 |
Second : | 6.57 |
| Pivot price | 4.72 |
|||
| Supports | First : | 3.4 | Second : | 2.82 |
| MAs | MA(5) : | 3.93 |
MA(20) : | 4.95 |
| MA(100) : | 6.48 |
MA(250) : | 9.6 |
|
| MACD | MACD : | -0.7 |
Signal : | -0.6 |
| %K %D | K(14,3) : | 14.6 |
D(3) : | 13 |
| RSI | RSI(14): 34 |
|||
| 52-week | High : | 29.06 | Low : | 3.4 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ PHIO ] has closed above bottom band by 26.2%. Bollinger Bands are 48.7% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 1 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 4.07 - 4.09 | 4.09 - 4.11 |
| Low: | 3.51 - 3.53 | 3.53 - 3.55 |
| Close: | 3.95 - 3.98 | 3.98 - 4.02 |
Phio Pharmaceuticals Corp. develops immuno-oncology therapeutics in the United States. It offers INTASYL therapeutic platform focuses on targeting tumor and immune cells by regulating genes of the immune system. The company develops PH-762 that activates immune cells to recognize and kill cancer cells by reducing the expression of the checkpoint protein PD-1 for immunotherapy in adoptive cell transfer (ACT); PH-894 that silences the epigenetic protein BRD4, which is an intracellular regulator of gene expression for use in ACT; and PH-804 that targets the suppressive immune receptor TIGIT, which is a checkpoint protein present on T cells and natural killer cells for use in ACT. It has collaborations with AgonOx Inc. on clinical development of novel T cell-based cancer immunotherapies. The company was formerly known as RXi Pharmaceuticals Corporation and changed its name to Phio Pharmaceuticals Corp. in November 2018. Phio Pharmaceuticals Corp. was incorporated in 2011 and is headquartered in Marlborough, Massachusetts.
Thu, 25 Jul 2024
Phio Pharmaceuticals regains Nasdaq compliance post-reverse split - Investing.com
Tue, 23 Jul 2024
PHIO hits 52-week low, trading at $3.8 - Investing.com
Fri, 12 Jul 2024
Phio Pharmaceuticals announces reduced-price warrant exercise - Investing.com
Fri, 12 Jul 2024
Phio Pharmaceuticals Announces Exercise of Warrants for $3.1 Million Gross Proceeds - StockTitan
Fri, 12 Jul 2024
Phio Pharmaceuticals Announces Exercise of Warrants for $3.1 Million Gross Proceeds - Newsfile
Mon, 08 Jul 2024
Phio Pharmaceuticals Announces Addition of Clinical Trial Site for its Phase 1b study of PH-762 - Newsfile
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 1 (M) |
| Shares Float | 1 (M) |
| Held by Insiders | 0.6 (%) |
| Held by Institutions | 3.9 (%) |
| Shares Short | 16 (K) |
| Shares Short P.Month | 20 (K) |
| EPS | -22.69 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 10.97 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -69.7 % |
| Return on Equity (ttm) | -145.3 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -18.02 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -10 (M) |
| Levered Free Cash Flow | -6 (M) |
| PE Ratio | -0.18 |
| PEG Ratio | 0 |
| Price to Book value | 0.36 |
| Price to Sales | 0 |
| Price to Cash Flow | -0.21 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|